Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
August 23, 2004
- 1st Qtr Business Results
August 23, 2004
- Chugai to Strengthen Antibody Drug Business by Transferring OTC Business to Lion
August 23, 2004
- OTC NEWS IN BRIEF
August 23, 2004
- BUSINESS NEWS IN BRIEF
August 23, 2004
- Korosho Calls For Proper Use of Cypher Stents, Ticlopidine
August 23, 2004
- Chugai to Transfer OTC Drug Business to Lion
August 9, 2004
- UFT Postoperative Adjuvant Chemotherapy Effective against Rectal Cancer: Taiho Seminar
August 9, 2004
- Kobayashi Embarks on Reorganization Effort
August 9, 2004
- PRESS SEMINAR
August 9, 2004
- OTC NEWS IN BRIEF
August 9, 2004
- NEW PRODUCTS
August 9, 2004
- MEDICAL DEVICE NEWS IN BRIEF
August 9, 2004
- Semi-annual Business Results
August 9, 2004
- 1st Qtr Business Results
August 9, 2004
- Annual Business Results
August 9, 2004
- DIAGNOSTIC NEWS IN BRIEF
August 9, 2004
- 1st Qtr Business Results
August 9, 2004
- BULLETIN
August 9, 2004
- BUSINESS NEWS IN BRIEF
August 9, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…